However, we did not find any significant association between BIM deletion polymorphism and clinical outcome of Bcl-Abl tyrosine kinase-driven CML and HCC in terms of RR, DCR, PFS and OS. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.